Collaborations to Enhance Drug Development and Regulatory Science
FDA grant supports collaborative projects to advance drug development, manufacturing, and regulatory science, focusing on safety, efficacy, and innovation.
Funder: Food and Drug Administration
Due Dates: Forecasted (no current deadline posted)
Funding Amounts: Up to $5,000,000 per award; multiple awards possible; project period and total program funding not specified.
Summary: FDA grant supports collaborative projects to advance drug development, manufacturing, and regulatory science, focusing on safety, efficacy, and innovation.
Key Information: This is a forecasted opportunity; application details and deadlines will be announced.
Description
This forecasted opportunity from the Food and Drug Administration (FDA) invites applications for cooperative agreements to support, manage, and facilitate public-private partnerships and collaborative activities as part of the Critical Path Initiative. The goal is to advance regulatory science and foster innovation in drug development, manufacturing, and translation of basic science into therapeutics. Projects will be developed collaboratively with the FDA and may include research, education, and outreach activities that:
- Accelerate drug product development
- Support advanced manufacturing approaches
- Facilitate translation of basic science discoveries into therapeutics
- Enhance the safety, efficacy, quality, and performance of drug products
Projects are identified by the FDA and are directly dependent on current drug development priorities and funding availability.
